Merck Continues Looking For The “Right” Biotech Buying Opportunity
This article was originally published in The Pink Sheet Daily
Executive Summary
Speaking at a Goldman Sachs investor conference, CEO Clark discusses Merck’s plans in biotech.
You may also be interested in...
Merck’s Clark: 2009 is a Year of Fundamental Change
In 2009, Merck is implementing a new business model that fundamentally transforms the company and is crucial to its future, CEO Richard Clark told analysts at a Goldman Sachs health care conference Jan. 7
Merck Announces Major FOB Initiative With Its New Business Unit
Merck BioVentures plans to launch follow-on version of Amgen’s Aranesp by 2012.
Can Big Pharma Save Biotech Investors?
Want to know how bad off small biotechs are these days? Investment bankers are so desperate to unload companies, they've taken to calling on corporate development departments with lists of "wounded animals" - those companies with just a few months of cash remaining, according to a business development head at a big pharmaceutical company